Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).
J Clin Oncol. 2020 Jun 10;38(17):1919-1927. doi: 10.1200/JCO.19.03077. Epub 2020 Mar 24.
J Clin Oncol. 2020.
PMID: 32208960
Clinical Trial.